B+
Bull case
20%
Probability
Target price
$425.00
+29.5% vs current
AMGN
AmgenCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
60%
Probability
Target price
$333.98
+1.7% vs current
B-
Bear case
20%
Probability
Target price
$180.00
-45.2% vs current
AI sentiment snapshot
Latest data as of 2026-01-23
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+46.7
Score
AI commentary
Market tone is mixed: consensus median near $333.98 with a wide spread (low $180 to high $425), indicating divergent views on pipeline and biosimilar risk. Near-term sensitivity centers on the upcoming earnings window and late-stage readouts.
RankAlpha Sentiment AI - 2026-01-23
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-04-23catalystFY2025 Q4 earnings & guidanceMedium impact
Quarterly results and guidance update; market sensitivity to revenue, biologics demand, and buyback commentary.
2026-04-23catalystCapital-allocation update (buybacks/dividend)Medium impact
Management announcements on buybacks or dividend policy can re-rate shares and shift investor expectations.
2027-01-23eventLate-stage readouts & regulatory milestonesHigh impact
Potential late-stage trial readouts or FDA/EMA decisions; approvals lift value, failures or delays are negative.
Recommendation
N/A
No formal recommendation provided.
As of 2026-01-23 • Updated nightlySource: Internal modelMethodology